Close menu




January 6th, 2022 | 13:14 CET

Heidelberger Druck, wallstreet:online, Alibaba: When new business brings 271% returns

  • Investments
Photo credits: pixabay.com

When companies break new ground, there are risks but also opportunities. If we look at large corporations, they have repeatedly provided innovations in the past - especially in industries where technology is advancing. Here we take a look at three companies undergoing change and explain how great the potential is and whether investors can learn anything from these examples.

time to read: 3 minutes | Author: Nico Popp
ISIN: HEIDELBERG.DRUCKMA.O.N. | DE0007314007 , WALLSTREET:ONLINE INH ON | DE000A2GS609 , ALIBABA GR.HLDG SP.ADR 8 | US01609W1027

Table of contents:


    Heidelberger Druck: From boring to innovative

    The Heidelberger Druck share was long considered boring. And uninteresting. As a manufacturer of high-precision printing presses, Heidelberger Druck benefited from its know-how but suffered from dwindling sales in the traditional print business. As a countermeasure, the Company invested in IT companies with a focus on software related to the digitization of technical documentation. Heidelberger Druck wanted to offer solutions and earn a stake in almost every area where companies needed to become digitally more efficient. The idea at the time was a good one - but it still failed. In 2021, the software subsidiary was sold again. In the meantime, the Company has been extraordinarily successful in a completely different area: namely, with wallboxes for electromobility.

    A few years ago, Heidelberger Druck discovered that it had quite a lot to offer in manufacturing the wallboxes itself, which are subsidized by KfW. Most recently, the fledgling business unit grew by a staggering 190% within a year. For the formerly beleaguered Company from a struggling industry, the new business is a fountain of youth. Heidelberger Druck is now worth around EUR 800 million and is no longer a penny stock. After 271% in one year, the share stands at over EUR 3. The example of Heidelberger Druck shows the power that can be found in traditional industrial companies when they break new ground. Although analysts expect growth to slow in the coming months, the share remains a success story.

    wallstreet:online: Growth for tomorrow's success

    A true success story is also wallstreet:online. In recent years, the operator of stock market portals and financial news websites has also reinvented itself. With its Smartbroker, wallstreet:online took off in the competitive broker market and won many customers. The recipe for success: lean fees despite good service. In this way, wallstreet:online has succeeded in keeping up with major players such as Trade Republic in terms of customer assets under management. The prospects for wallstreet:online also look good. Because of its business with stock exchange forums, around 830,000 registered users cavort on the Company's pages. Much of the content can also be accessed without registration.

    In the age of social media, wallstreet:online thus has clear advantages over competitors who have to buy every new customer at great expense via a marketing budget. In the future, the Smartbroker is to be integrated even better into the media offering, for example, by means of trading buttons in the editorial environment. The path to sales for the Smartbroker would then be particularly short. Until then, the Company is still focusing strongly on growth and is also investing heavily. This approach also makes sense - the stronger wallstreet:online grows, the bigger the cake that can be distributed in a few years. Last year, the share reached the EUR 30 mark and can now be bought for EUR 22. When stock market sentiment brightens again, wallstreet:online should also profit again.

    Alibaba: Beijing declares war on hedonism

    Alibaba shareholders have been waiting for the share price to go up again for about a year. The Chinese Amazon actually has everything it needs to be a success story. The central government in Beijing, however, is now increasingly emphasizing the common good and has turned away from growth at all costs. This is also accompanied by stricter moral standards. One example is the strong regulation of video games. The days of unbridled consumption seem to be over in China for the time being. For many months, this has weighed on Alibaba's share price. Over the course of a year, the stock has lost around 43%. A bottom could form in the EUR 100 range, below which things are likely to get uncomfortable. Alibaba is a promising digital company, but Beijing restricts the market. Caution is warranted here!


    When companies break new ground with innovation, it can mean a groundbreaking turnaround - as in the case of Heidelberger Druck. It is even better when new business and traditional offerings complement each other, as in the case of wallstreet:online. However, investors should be sure to evaluate business models in the light of the respective regulatory framework. The example of Alibaba is a good reminder that products and market conditions must be compatible for an investment to be successful.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read